Advertisement Pharmaceutical Business review -
Pharmaceutical Business review is using cookies

ContinueLearn More
Close
May 22, 2025

Juvenescence secures $76m funding to advance therapeutic pipeline

AI-enabled biotech company Juvenescence has announced the first close of its Series B-1 funding round, securing $76m to progress its therapeutic portfolio into clinical development.

The partnership will utilise M42's know-how in digital healthcare data, bioanalysis, genomics, and trial infrastructure. Credit: National Cancer Institute on Unsplash.